Xenon Pharmaceuticals
XENE
220 hedge funds and large institutions have $3.16B invested in Xenon Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 78 increasing their positions, 67 reducing their positions, and 19 closing their positions.
441% more call options, than puts
Call options by funds: $25.6M | Put options by funds: $4.73M
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
25% more capital inflows, than outflows
Capital inflows: $319M | Capital outflows: $255M
16% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 67
8% more funds holding
Funds holding: 204 → 220 (+16)
0.11% less ownership
Funds ownership: 97.53% → 97.42% (-0.11%)
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.7M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$24.6M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$19.2M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$41M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.6M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$24.1M |
| 4 |
Polar Capital Holdings
London,
United Kingdom
|
-$20.9M |
| 5 |
Braidwell
Stamford,
Connecticut
|
-$15.6M |
XENE Hedge Fund Activity: Q1 2024 in Review
220 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2024, worth a combined $3.16B — down 4.7% from $3.32B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new XENE positions and 19 closed out — a net gain of 16 holders — while 78 added to existing stakes and 67 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.5M. The largest seller was BVF Inc, exiting entirely with an estimated $41M sold.
- 220 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2024, up from 204 in Q4 2023.
- Funds reported $3.16B of Xenon Pharmaceuticals stock for Q1 2024, down 4.7% quarter-over-quarter.
- 35 funds opened new Xenon Pharmaceuticals positions in Q1 2024 and 19 closed out, a net change of +16 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $43.5M added.
- The largest Xenon Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2024.